An FDA Memo addressing First Amendment legal issues regarding off-label use of medical products falls short of the necessary clarity, write Jamie Kendall and Alexandra Schulz.
Jamie Kendall, Alexandra Schulz
Advertisement
Articles by Jamie Kendall, Alexandra Schulz
Advertisement
Latest Updated Articles
- What First Amendment? FDA Remains Unfazed By Off-Label Communication Issues
Published: March 7th 2017 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
2
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
3
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
4
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
5
